Company news
Racura Oncology Ltd (ASX:RAC) news
Racura Oncology Ltd news releases on 6ix. Latest, Jun 9, 2022: Race Oncology Announces On-Market Share Buyback
Press releases — page 3
Race Oncology Announces On-Market Share Buyback
June 8, 2022
EMD AML MDS Trial Expands to Europe
June 7, 2022
Zantrene AML trial in Israel advances to Phase 2
May 27, 2022
Race Receives Governance Approval for AML EMD & MDS Trial
May 11, 2022
Race receives Human Ethics AML Trial Approval
April 6, 2022
Supply Agreement for EMD AML Trial
March 30, 2022
Zantrene highly effective in EMD AML Mouse Model
March 16, 2022
Race Oncology : ASX Small and Mid-Cap Conference Presentation
March 14, 2022
Compelling Zantrene Preclinical Kidney Cancer Data
March 9, 2022
Race Oncology : Application for quotation of securities - RAC
March 6, 2022
MD Anderson Preclinical AML Study on Zantrene Published
February 22, 2022
Race raises $29.7 million in oversubscribed SPP
December 20, 2021
Expanded Heart Protection Discovery for Zantrene
December 7, 2021
Race Oncology : Notification regarding unquoted securities - RAC
December 3, 2021
Race Oncology Investor Presentation - November 2021
November 23, 2021
AGM Presentations
November 22, 2021
Breakthrough Zantrene Heart Protection Discovery
November 21, 2021
University of Wollongong R&D Collaboration
November 8, 2021
Race secures sixth US patent for Zantrene
October 18, 2021
Race secures fifth US patent for Zantrene
October 5, 2021
Preclinical & Clinical Programs Update
September 30, 2021
Zantrene highly effective in Melanoma preclinical study
September 29, 2021
First Patient Dosed in Phase 1b/2 AML Trial
August 9, 2021
Race executes Israel AML Phase 2 Trial Contract
June 21, 2021
Race Executes Key Contract for Israel Phase 2 AML Trial
June 7, 2021
Contract to Commence Phase 2 Extramedullary AML Trial
June 1, 2021
Prospectus
May 5, 2021
Race investor briefing & updated presentation
May 4, 2021
Race Initiates Heart Safety Preclinical Study for Bisantrene
April 27, 2021
Second independent study shows Bisantrene inhibits FTO
April 15, 2021
Race Strategic Update March 2021
March 30, 2021
Race Initiates Extramedullary AML Preclinical Study
March 29, 2021
Race Initiates FTO Directed Kidney Cancer Preclinical Study
March 24, 2021
Race Initiates FTO Melanoma Preclinical Study
March 18, 2021
S&P DJI Announces March 2021 Quarterly Rebalance
March 12, 2021
Compelling Preclinical Breast Cancer Results
March 8, 2021
Race receives $387k R&D tax incentive refund
December 16, 2020
Race AGM presentations and strategic update
November 29, 2020
Impressive Preclinical Bisantrene Breast Cancer Results
November 23, 2020
Prof Borje S Andersson appointed Chief Medical Officer
October 1, 2020
Race leadership team strengthened
September 1, 2020
Strategic investors make further $1.5m investment in Race
August 12, 2020
A$3m strategic investment from prominent biotech investors
July 12, 2020
Extension of time to repay loan through share buy-back
June 16, 2020
Impressive 40% response in Phase II Bisantrene AML Trial
June 15, 2020
Managing Director Resignation
May 20, 2020
Race starts preclinical breast cancer study for Bisantrene
May 13, 2020
Race Secures A$1.8m strategic placement
March 5, 2020
December 2019 Quarterly Report
January 29, 2020
Race Receives $159k R&D Tax Incentive Refund
December 16, 2019